Market Data graphic

Life Sciences

You are here

The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.

Life sciences companies listed on CSE

4Front Ventures Corp. is a vertically-integrated cannabis company with cultivation, production and retail facilities spread across several states in the US.

Share Classes

4Front has two classes of shares: subordinate voting shares (“SVS”) and multiple voting shares (“MVS”). SVS are publicly traded on the CSE and are entitled to one vote.  MVS are not publicly traded, can convert to SVS at a ratio of 1 MVS to 1 SVS, and are entitled to 800 votes per MVS.

There are 592,644,240 SVS outstanding and 1,276,208 MVS convertible to 1,276,208 outstanding for a total outstanding SVS of 593,920,448 on an as-converted basis.

Please see Section 10 - Description of Securities of 4Front's Form 2A Listing Statement for a further description of the SVS and MVS.

Each Warrant entitles the holder thereof, upon exercise at any time after the Issue Date and prior to the Expiry Time, to acquire one (1) Warrant Share upon payment of the Exercise Price of $0.90.

See the Warrant Indenture for full details.

Headquartered in New York City, Acreage is a vertically integrated, multi-state operator of cannabis ‎licenses and assets in the U.S. Acreage is dedicated to building and scaling operations to create a ‎seamless, consumer-focused branded cannabis experience. Acreage debuted its national retail store ‎brand, The Botanist in 2018 and its award-winning consumer brands, The Botanist and Live Resin Project ‎in 2019.‎

Class E subordinate voting share (each, a “Fixed Share”) of the Company was created pursuant to the Amended Plan of Arrangement.  Each Fixed Share entitles the holder to one vote per share at shareholder meetings of the Company. Each Fixed Share is subject to an option (the “Canopy Option”) in favour of Canopy Growth Corporation (“Canopy Growth”) pursuant to which Canopy Growth may, upon satisfaction or waiver of the conditions set out in the Amended Arrangement Agreement, acquire the Fixed Shares (the “Acquisition”).  The  Canopy Option is required to be exercised upon the occurrence of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana and subject to the satisfaction or waiver of certain conditions to closing as set out in the Amended Arrangement Agreement, the Acquisition will be completed.

Investor Note: In addition to the 71,343,094 Fixed Shares and 30,626,805 Floating Shares that are listed and trading, there are 17,017,664 Fixed Shares and 7,242,885 Floating Shares, respectively, reserved for issuance pursuant to redemption and conversion rights attached to other share classes of Acreage Holdings, Inc., as well as certain outstanding securities of Acreage Holdings WC, Inc. and High Street Capital Partners, LLC, which are subsidiaries of Acreage Holdings, Inc. The total number of Fixed Shares and Floating Shares, as converted, is 88,360,758 and 37,869,690, respectively, excluding options, warrants, RSUs and convertible debt.

 

Headquartered in New York City, Acreage is a vertically integrated, multi-state operator of cannabis ‎licenses and assets in the U.S. Acreage is dedicated to building and scaling operations to create a ‎seamless, consumer-focused branded cannabis experience.

A Class D subordinate voting share (each, a “Floating Share”) of the Company was created pursuant to the Amended Plan of Arrangement.  Each Floating Share entitles the holder thereof to one vote per share at shareholder meetings of the Company. Each Fixed Share is subject to an option in favor of Canopy Growth (the “Floating Call Option”) to acquire all of the issued and outstanding Floating Shares.  If exercised in accordance with the terms of the Amended Plan of Arrangement, Canopy Growth’s acquisition of the Floating Shares will take place concurrently with, and subject to satisfaction or waiver of the same conditions as, the Acquisition.

Investor Note: In addition to the 71,343,094 Fixed Shares and 30,626,805 Floating Shares that are listed and trading, there are 17,017,664 Fixed Shares and 7,242,885 Floating Shares, respectively, reserved for issuance pursuant to redemption and conversion rights attached to other share classes of Acreage Holdings, Inc., as well as certain outstanding securities of Acreage Holdings WC, Inc. and High Street Capital Partners, LLC, which are subsidiaries of Acreage Holdings, Inc. The total number of Fixed Shares and Floating Shares, as converted, is 88,360,758 and 37,869,690, respectively, excluding options, warrants, RSUs and convertible debt.

Founded in 2014, Adastra Holdings Ltd. built a successful reputation as a household name in cannabis concentrates among consumers and retailers alike. Adastra Labs Inc. was founded in 2018 and is an agricultural-scale cannabis extraction, distillation, and product manufacturer, located in Langley, BC. Operating out of its 13,500 sq. ft. Health Canada Licensed Standard Processing facility, now named Adastra Holdings Ltd., produces and distributes cannabis-derived products designed for medical cannabis and forward-looking therapeutic use. Recently, the Company announced its entry into psychedelics by applying for a Controlled Substances Dealer's License, which is under review by Health Canada.

As a leading supplier, Adastra Holdings Ltd. currently distributes its product line to 1400+ adult-use retailers and a web-based medical platform, CannMart Inc., seeking to provide consistent, quality concentrate products and alternative treatment options across the country to patients.

Affinor is focused on the design, development and commercialization of vertical farming technology for both indoor and outdoor (greenhouse) applications. The team is currently working on demand crops such as romaine lettuce and strawberries by developing processes, methods and models to cultivate true perpetual crops at competitive pricing. It is the mission of Affinor to be the world-wide technology and market leader in creating and commercializing the most economical vertical farming technologies that use the least possible resources (eg. land, water, and energy resources) to produce the highest quality pesticide-free produce year-round, regardless of environmental conditions. Affinor’s patent technology and licensed patent pending technology positions the Company well in the vertical farming industry. It is the only vertically integrated technology that can offer patented inline automated pollination for fruiting crops. Affinor can offer software driven growing solutions automating high quality, scientifically engineered products and process.

AgraFlora Organics International Inc. has an experienced management team with a growth strategy to develop a diversified portfolio of projects that can be taken into production. The Company’s main objective is to add shareholder value through cost efficient acquisitions, joint ventures, and effective marketing while maintaining a lower risk profile through project diversification and sound financial management.

The Issuer is a digital health solutions provider utilizing a proprietary combination of digital health monitoring devices, AI based software, and a cloud computing platform which combine to help care givers, patients and healthcare professionals access and utilize relevant health data.

Aion Therapeutic Inc.  is an early-stage cannabinoid extraction company based in Oliver, BC. Aion has applied for a standard processing license under the Cannabis Act for its 10,410 ft2 facility and that application is currently in the review stage. The Company will offer contract tolling extraction, sale of bulk oil and development of both proprietary Aion Cannabis branded and white labelled products once licensed to do so.

Algernon Pharmaceuticals is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Contact The Team

How can we help you?

Contact the CSE team to find out more.

Advertisement

Publicité

Latest CSE News

Upcoming Events

2021-10-19_MJBizFinance_Website.jpg

MJBizFinance Forum

Tuesday, October 19, 2021 -
12:00pm to 8:00pm

Advertisement

Publicité